Commentary
Nature Biotechnology 25, 1390 - 1393 (2007)
doi:10.1038/nbt1207-1390
Antivirals—an increasingly healthy investment
Brian McCarthy1
- Brian McCarthy is Senior Biotechnology Analyst at Merriman Curhan Ford & Co., 520 Madison Avenue, Suite 901, New York, New York 10022, USA. He also holds an adjunct faculty position in Pharmacology and Neuroscience at the USUHS School of Medicine, Bethesda, MD, USA. e-mail: bmccarthy@mcfco.com
Abstract
Continued investment from big pharma and a slew of new drugs with novel mechanisms of action are fueling investor interest in the antiviral space.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Hepatitis HCV variability, the immune system and resistance to antiviral drugsNature Reviews Gastroenterology & Hepatology News and Views (01 Jul 2009)
